Synlogic (SYBX) 10-K2022 FY Annual report

Filed: 29 Mar 23, 6:31am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: Aeglea, AEs, AHR, appeal, Arrowhead, aryl, AUC, Avenge, Barrett, bioprinting, biopterin, bread, CFO, CHB, clinician, closure, complaince, Connecticut, consecutive, conversion, credibility, crucial, crystal, cyberattack, Cystadane, DDW, deadline, decarboxylase, delisted, delisting, developmental, disfavor, documentary, dysregulation, Dyve, energy, enriched, entailed, enterorecirculation, Escherichia, espionage, etiology, excise, experimental, familiar, fat, FDIC, fermentation, fog, genericization, genotoxic, genotype, geopolitical, grace, greatest, Hcy, Heffernan, HemoShear, HengRui, hepatic, Hope, Horizon, horizontal, hour, Hurter, hydrocarbon, idiopathic, infant, inflation, Inflationary, instability, internationally, IRA, Jensen, Jiangsu, lapse, Leschly, lifetime, Lisa, Lubkowicz, Lyndra, macroeconomic, malfunction, MetDC, Michael, microphysiological, mixed, mixing, motion, Nick, nonhuman, pasta, Patricia, PBM, Peter, Pharma, PheP, phishing, pPRV, precursor, predisposition, predominantly, Puurunen, receivership, retired, rice, RPDD, runway, Russia, sachet, SAE, Selecta, Shu, silico, Silvergate, SIMD, slower, starch, stolen, SVB, SVP, swept, tailored, TCJA, threat, TID, tighter, transient, Travere, Turnstone, Ukraine, unamortized, unified, uninsured, Unitary, Uox, UPC, uric, Utah, Valley, vast, Venture, volunteer, voucher, wage, water, White

Removed: adalimumab, Allena, ASU, Beloff, burdened, Century, cinnamic, clinic, cofactor, degradation, digestion, discontinue, discontinuing, discovering, dysfunctional, easy, emerge, enhanced, expanding, Gregg, headcount, Hedging, hippuric, Humira, immunologic, infancy, leader, learned, localized, maple, Med, medium, moderately, modernize, mouse, MSUD, poor, post, presidential, primate, psychiatric, randomized, recirculating, repeal, rest, spur, struggle, subgroup, syrup, temporarily, tetrahydrobiopterin, transformative, ulcerative, Vol, wiring, worsening

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

SYBX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Synlogic, Inc. (the “Company”) on Form 10-K for the period ending December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Aoife Brennan, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.


Date: March 29, 2023	By:	/s/ AOIFE BRENNAN
		Aoife Brennan
		President and Chief Executive Officer (Principal Executive Officer)

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.